Representative Matters

• Representing Novo Nordisk in pending Hatch-Waxman patent infringement lawsuits brought against six generic pharmaceutical manufacturers concerning Novo Nordisk’s blockbuster type 2 diabetes therapy and best-selling product Ozempic®.
• Representation of Novo Nordisk in a series of Hatch-Waxman patent litigations dating back to 2017 relating to its blockbuster diabetes drug Victoza®, including ongoing cases against three ANDA filers. Prevailed in claim construction proceedings against all opponents in previous litigations, which helped lead to confidential settlements in each matter.
• Representation of Swiss biopharmaceutical company IBSA in Hatch-Waxman litigations concerning its products Flector® and Tirosint®, including ongoing litigation related to its hypothyroidism treatment product Tirosint®-SOL.
• Representing Novo Nordisk in pending patent infringement lawsuits brought against four ANDA filers concerning Novo Nordisk’s weight-loss treatment Saxenda®.
• Obtained highly favorable settlement for Pharmacosmos A/S and Pharmacosmos Therapeutics in patent litigation brought by a competitor in relation to Pharmacosmos’ newly launched iron deficiency anemia treatment Monoferric®.
• Represented Pfizer and UCB in a series of District Court and PTAB trials concerning the drug Toviaz®. In the first trial against five defendants, the District Court ruled in Pfizer and UCB’s favor on all issues. In the second trial, the District Court ruled in Pfizer and UCB’s favor on all issues immediately upon the close of evidence. The PTAB upheld all challenged claims in UCB’s patents and the Federal Circuit affirmed.
• Represented Pfizer as petitioner in an inter partes review concerning methods of treating lymphoma using monoclonal antibodies and chemotherapy. The PTAB cancelled all challenged claims as unpatentable over the prior art.
• Represented Novo Nordisk as patent owner in an inter partes review filed by a competitor concerning methods of nanofiltering recombinant therapeutic proteins. The PTAB upheld all challenged claims in Novo Nordisk's patent.
• Represented Pfizer at trial in a patent infringement case against eight generic manufacturers concerning the blockbuster pain and epilepsy drug Lyrica®. The U.S. District Court for the District of Delaware ruled in Pfizer's favor on all issues and the Federal Circuit affirmed.
• Represented a pop-up COVID testing company as defendant in contesting an emergency motion for a temporary restraining order (“TRO”) halting its business based on breach of contract and IP misuse claims. The court denied the TRO.
• Represented Pfizer in a class action lawsuit concerning the drug Celebrex® arising under federal and state antitrust and unfair competition laws.
• Represented a large pharmaceutical company in a class action antitrust lawsuit concerning the drug Namenda®.
• Represented foreign wireless telecommunications carriers as defendants in a patent infringement action involving over 130 parties. The U.S. District Court for the District of Maryland granted our motion to dismiss the foreign carriers for lack of personal jurisdiction, and the Federal Circuit affirmed.
• Represented a large consumer products company in various patent infringement matters, including cases concerning internet encryption technology and social media marketing.